Variation in outpatient antibiotic prescribing in the United States.

Michael A Steinman, Katherine Y Yang, Sepheen C Byron, Judith H Maselli, Ralph Gonzales
Author Information
  1. Michael A Steinman: San Francisco VA Medical Ctr, 4150 Clement St, Box 181-G, San Francisco, CA 94121, USA. mike.steinman@ucsf.edu

Abstract

OBJECTIVE: To evaluate variation in outpatient antibiotic utilization among US commercial health plans and the implications of this variation for cost and quality.
STUDY DESIGN AND METHODS: We measured antibiotic utilization rates among 229 US commercial health plans that participated in the 2005 Healthcare Effectiveness Data and Information Set. Rates were adjusted to account for health plan age and sex distribution. To estimate antibiotic costs, we multiplied utilization data for each drug class by national estimates of intraclass distribution of drugs, duration of therapy, and median average wholesale price.
RESULTS: Antibiotic utilization rates varied markedly among plans, ranging from 0.64 antibiotic fills per member per year (PMPY) at the 5th percentile of plans to 1.08 fills PMPY at the 95th percentile, with a mean of 0.88 (SD +/- 0.15) antibiotic fills PMPY. US census region was the strongest predictor of antibiotic utilization. Antibiotic costs averaged $49 PMPY and ranged from $34 to $63 PMPY among plans at the 5th and 95th percentiles of cost, respectively. If a health plan with 250,000 members at the 90th percentile of antibiotic costs reduced its costs to the 25th percentile, annual drug cost savings would be approximately $4.1 million.
CONCLUSIONS: Antibiotic utilization varies substantially among commercial health plans and is not accounted for by differences in the age and sex distribution of plan members. Because reducing rates of antibiotic utilization is likely to lower costs and improve quality, high-utilizing plans may reap considerable rewards from investing in programs to reduce the overuse of antibiotics.

References

  1. Lancet. 2001 Jun 9;357(9271):1851-3 [PMID: 11410197]
  2. JAMA. 1993 May 26;269(20):2633-6 [PMID: 8487445]
  3. Clin Ther. 2005 Feb;27(2):258-62 [PMID: 15811491]
  4. Med Decis Making. 1993 Oct-Dec;13(4):293-301 [PMID: 8246701]
  5. Lancet. 2005 Feb 12-18;365(9459):579-87 [PMID: 15708101]
  6. Am J Infect Control. 2007 Oct;35(8):521-6 [PMID: 17936143]
  7. Clin Infect Dis. 2001 Sep 15;33(6):757-62 [PMID: 11512079]
  8. Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):115-23 [PMID: 16700079]
  9. Med Care. 2008 Aug;46(8):847-62 [PMID: 18665065]
  10. MMWR Morb Mortal Wkly Rep. 1999 Aug 6;48(30):656-61 [PMID: 10488781]
  11. Ann Intern Med. 2003 Apr 1;138(7):525-33 [PMID: 12667022]
  12. Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1152-6 [PMID: 9927709]
  13. Clin Infect Dis. 2007 Apr 15;44(8):1091-5 [PMID: 17366456]
  14. N Engl J Med. 2000 Dec 28;343(26):1917-24 [PMID: 11136262]
  15. Public Health. 2006 Aug;120(8):752-9 [PMID: 16828131]
  16. Qual Saf Health Care. 2007 Dec;16(6):440-5 [PMID: 18055888]
  17. JAMA. 1999 Feb 17;281(7):627-33 [PMID: 10029124]
  18. JAMA. 2001 Sep 12;286(10):1181-6 [PMID: 11559262]
  19. N Engl J Med. 1997 Aug 14;337(7):441-6 [PMID: 9250845]
  20. Med Care. 2000 Oct;38(10):981-92 [PMID: 11021671]
  21. Clin Infect Dis. 2008 Sep 15;47(6):735-43 [PMID: 18694344]
  22. BMJ. 1998 Sep 5;317(7159):637-42 [PMID: 9727992]
  23. Ann Intern Med. 1998 May 15;128(10):866-8 [PMID: 9599201]
  24. Br J Clin Pharmacol. 2004 Oct;58(4):419-28 [PMID: 15373935]
  25. Int J Qual Health Care. 1998 Oct;10(5):443-7 [PMID: 9828034]
  26. Am J Public Health. 2003 Nov;93(11):1910-4 [PMID: 14600065]

Grants

  1. K23 AG030999-02/NIA NIH HHS
  2. K23 AG030999/NIA NIH HHS
  3. KL2 RR024130/NCRR NIH HHS
  4. K23-AG030999/NIA NIH HHS
  5. R01 HS013915/AHRQ HHS
  6. R01 HS13915/AHRQ HHS

MeSH Term

Adolescent
Adult
Ambulatory Care
Anti-Bacterial Agents
Child
Child, Preschool
Cost Savings
Female
Humans
Infant
Infant, Newborn
Male
Managed Care Programs
Middle Aged
Practice Patterns, Physicians'
United States
Young Adult

Chemicals

Anti-Bacterial Agents

Word Cloud

Created with Highcharts 10.0.0antibioticutilizationplansamonghealthcostsPMPYpercentileUScommercialcostratesplandistributionAntibiotic0fillsvariationoutpatientqualityagesexdrugper5th195thmembersOBJECTIVE:evaluateimplicationsSTUDYDESIGNANDMETHODS:measured229participated2005HealthcareEffectivenessDataInformationSetRatesadjustedaccountestimatemultiplieddataclassnationalestimatesintraclassdrugsdurationtherapymedianaveragewholesalepriceRESULTS:variedmarkedlyranging64memberyear08mean88SD+/-15censusregionstrongestpredictoraveraged$49ranged$34$63percentilesrespectively25000090threduced25thannualsavingsapproximately$4millionCONCLUSIONS:variessubstantiallyaccounteddifferencesreducinglikelylowerimprovehigh-utilizingmayreapconsiderablerewardsinvestingprogramsreduceoveruseantibioticsVariationprescribingUnitedStates

Similar Articles

Cited By